Dupilumab: a potential new treatment for severe asthma

Affiliations

¹ Experimental Studies Unit, National Heart & Lung Institute, Imperial College London, UK; Biomedical Research Unit, Royal Brompton & Harefield NHS Trust, London SW3 6LY, UK. Electronic address: f.chung@imperial.ac.uk.

Comment

Kian Fan Chung. Lancet. 2016.

. 2016 Jul 2;388(10039):3-4.

doi: 10.1016/S0140-6736(16)30311-7. Epub 2016 Apr 27.

¹ Experimental Studies Unit, National Heart & Lung Institute, Imperial College London, UK; Biomedical Research Unit, Royal Brompton & Harefield NHS Trust, London SW3 6LY, UK. Electronic address: f.chung@imperial.ac.uk.

No abstract available

Comment on

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A. Wenzel S, et al. Lancet. 2016 Jul 2;388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5. Epub 2016 Apr 27. Lancet. 2016. PMID: 27130691 Clinical Trial.